PT-141 represents a cutting-edge cyclic melanocortin agonist that exhibits potential in the treatment of sexual dysfunction. This novel compound operates by activating specific receptors within the body, leading to augmented sexual function. Preclinical studies have indicated that PT-141 may significantly treat a spectrum of sexual dysfunctions in